Synthetic Biologics Inc (SYN) : During the past 4 weeks, traders have been relatively bearish on Synthetic Biologics Inc (SYN), hence the stock is down -12.75% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -3.84% relative to the S&P 500. The 4-week change in the price of the stock is -10.58% and the stock has fallen -3.43% in the past 1 week.
Synthetic Biologics Inc (NYSEMKT:SYN): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $1.75 and $1.65 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $1.75. The buying momentum continued till the end and the stock did not give up its gains. It closed at $1.69, notching a gain of 0.60% for the day. The total traded volume was 415,521 . The stock had closed at $1.68 on the previous day.
The stock has recorded a 20-day Moving Average of 2.99% and the 50-Day Moving Average is 7.81%. Synthetic Biologics Inc. has dropped 25.22% during the last 3-month period . Year-to-Date the stock performance stands at -26.2%.
Synthetic Biologics Inc (SYN) : Average target price received by Synthetic Biologics Inc (SYN) is $8.25 with an expected standard deviation of $0.96. The most aggressive target on the stock is $9, whereas the most downbeat target is $7. 4 financial analysts are currently covering the stock.
Synthetic Biologics, Inc. is a clinical-stage biotechnology company. The Company is developing pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome. It is developing an oral biologic to protect the gut microbiome (gastrointestinal (GI) microflora) from intravenous (IV) antibiotics for the prevention of C. difficile infection, an oral statin treatment to reduce the impact of methane producing organisms on irritable bowel syndrome with constipation (IBS-C) and a monoclonal antibody combination for the treatment of Pertussis. In addition, the Company is developing a Phase II oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.